ArticleJournal of neurosurgery. Case lessons2025
Chronic expanding hematoma following Gamma Knife irradiation for primary central nervous system lymphoma: illustrative case.
Article in Journal of neurosurgery. Case lessons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic expanding hematoma (CEH) is a rare disease characterized by slow expansion, especially reported after Gamma Knife radiosurgery (GKRS) for cerebral arteriovenous malformations. No cases have been reported following treatment for primary central nervous system lymphoma (PCNSL). Vascular endothelial growth factor and vascular endothelial growth factor receptor-1 (VEGFR-1) have been reported to be responsible for CEH induction. OBSERVATIONS: A 56-year-old woman underwent partial tumor removal for PCNSL in the left temporo-occipital lobe at another hospital. One and a half months later, a new lesion was observed, and she underwent GKRS, including the residual lesion. She was treated with multiple chemotherapy regimens including R-MPV (rituximab, methotrexate, procarbazine, vincristine) but relapsed repeatedly and was administered tirabrutinib. Four years after GKRS, the gadolinium-enhanced lesion slowly grew. Tumor recurrence or radiation necrosis was suspected, and surgical removal was performed. The tissue was composed of nonmalignant brain tissue and fibrinized hematoma, which demonstrated strong expression of VEGFR-1 on immunostaining, and the pathological diagnosis was CEH. LESSONS: In this patient, CEH could have resulted from VEGFR-1 expression due to GKRS. For a patient with slow lesion growth following GKRS for PCNSL, surgical removal should be considered, taking into account the possibility of CEH along with recurrence and radiation necrosis. https://thejns.org/doi/10.3171/CASE258.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.